Adcetris is indicated for the treatment of patients with classical Hodgkin Lymphoma at high risk of relapse or progression as post-auto-HSCT consolidation.

Subtype:

Hodgkin Lymphoma (HL)

License:

FDA

Class:

CD30 ADC

R/R

PIhttp://www.seattlegenetics.com/pdf/adcetris_USPI.pdf 

1. Approved Labelling 

Adcetris is indicated for the treatment of patients with classical Hodgkin Lymphoma at high risk of relapse or progression as post-auto-HSCT consolidation.

2. Treatment Regimen 

Administer Adcetris as an intravenous infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity. The recommended dose is 1.8 mg/kg. Reduce dose in patients with mild hepatic impairment.

For classical HL post-auto-HSCT consolidation treatment, initiate Adcetris treatment within 4–6 weeks post-auto-HSCT or upon recovery from auto-HSCT. These patients should continue treatment until a maximum of 16 cycles, disease progression, or unacceptable toxicity.

3. AE/Warnings 

Please see section 5 of the PI.

 

 

 

All content on this site is intended for healthcare professionals only. If you are a patient or carer, please visit the Lymphoma Coalition.